Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. (NASDAQ: FLGT) regularly issues news and updates that reflect its dual focus on laboratory services and oncology therapeutic development. Company press releases cover topics such as quarterly and annual financial results, clinical trial progress for its cancer drug candidates, regulatory milestones for its genomic testing platforms, and strategic transactions in the laboratory and pathology space. Because Fulgent describes itself as a technology-based company with ambitions in precision medicine, its news flow often highlights both operational performance and advances in its technology and therapeutic pipelines.
Investors following FLGT news can expect detailed earnings releases that discuss revenue, core revenue, GAAP and non-GAAP results, gross margins, and adjusted EBITDA, along with commentary from management on business trends in the laboratory services and therapeutic development segments. The company also announces the timing of upcoming earnings calls and investor conference presentations through news releases, providing context for when management will discuss the business with the investment community.
Beyond financial reporting, Fulgent’s news includes updates on its oncology programs, such as preliminary clinical data from trials of FID-007 in recurrent or metastatic head and neck squamous cell carcinoma. The company also reports on regulatory achievements, including CE certification in the European Union for its FulgentExome and Fulgent Pipeline Manager (PLM) germline next-generation sequencing system. In addition, Fulgent uses press releases to announce strategic moves in laboratory and pathology services, such as its agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx.
This FLGT news page aggregates these types of announcements so readers can review financial disclosures, clinical development updates, technology milestones, and transaction-related news in one place. For those tracking Fulgent’s progress toward its stated goal of becoming a fully integrated precision medicine company, the news feed provides an ongoing view of how the company reports its operational and strategic developments.
Summary not available.
Fulgent Genetics (NASDAQ: FLGT) announced it will release its Q2 2021 financial results on August 5, 2021, after market close. Following this, a conference call will be hosted by CEO Ming Hsieh and other executives at 4:30 PM ET to discuss the results and answer questions. The company’s innovative technology platform offers extensive testing solutions, including full-gene sequencing and tailored options, ensuring high accuracy and competitive turnaround times, aimed to address diverse customer needs.
Fulgent Genetics (NASDAQ: FLGT) has announced a strategic investment of approximately $19 million in FF Gene Biotech, increasing its stake and control in the Chinese entity formed through a Joint Venture. This investment aims to enhance Fulgent's presence in China's rapidly growing genetic testing market, projected to reach $4.5 billion by 2030. The Joint Venture has generated over $10 million in revenue since inception, focusing on cancer, reproductive health, and pediatrics testing. This move is expected to positively impact Fulgent's consolidated financial results.
Fulgent Genetics (NASDAQ: FLGT) reported a remarkable first quarter for 2021, achieving a revenue of $359.4 million, representing an increase of 4,500% compared to $7.8 million in Q1 2020. The company recorded a GAAP income of $200.7 million or $6.52 per share. Expectations for Q2 are around $200 million in revenue, with a full-year forecast raised to $830 million, a 97% year-over-year growth. Significant contributions are anticipated from both RT-PCR and NGS testing, with GAAP income projected at $380 million for 2021.
Fulgent Genetics (NASDAQ: FLGT) will release its Q1 2021 financial results on May 6, 2021, after market close. A conference call for investors will follow at 4:30 PM ET, hosted by CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis. The call can be accessed via a live audio webcast or by dialing (800) 353-6461 with code 9490797. Fulgent’s advanced technology platform offers a wide array of genetic testing solutions, including RT-PCR tests for COVID-19, with Emergency Use Authorization from the FDA.
Fulgent Genetics has been awarded a contract by the CDC to conduct ongoing genomic sequencing of SARS-CoV-2 samples using its Next Generation Sequencing (NGS) capabilities. This partnership aims to facilitate a large-scale genomic survey of the virus, crucial for understanding transmission patterns and identifying emerging variants. The CDC's initiative is expected to enhance public health responses to COVID-19. Fulgent's expertise in COVID-19 testing solutions positions it as a key player in this critical research effort.
Fulgent Genetics (NASDAQ: FLGT) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. The company's executives, including Chairman and CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, will host a presentation at 8:40 a.m. ET.
A live webcast of the event will be accessible via the Investor Relations section of Fulgent Genetics' website.
Fulgent Genetics, Inc. (NASDAQ: FLGT) reported record fourth quarter 2020 results with revenue of $295.0 million, a remarkable 3,400% increase year-over-year. The company achieved GAAP income of $166.3 million or $6.16 per share. Full-year revenue was $421.7 million, up 1,200% from 2019. Looking ahead to 2021, Fulgent anticipates overall revenue of approximately $800.0 million, reflecting a 90% growth. Non-COVID revenue grew 43% in Q4, and the company continues to expand its testing capabilities and customer base.
Fulgent Genetics (NASDAQ: FLGT) announced it will release its Q4 and full-year 2020 financial results on March 4, 2021, after market close. The company's CEO Ming Hsieh and other executives will host a conference call to discuss the results at 4:30 PM ET (1:30 PM PT). Investors can access the call via a live audio webcast or by dialing (855) 321-9535 with conference ID 7669989. A replay will be available until March 11, 2021.
Fulgent's technology platform offers comprehensive testing solutions, including SARS-CoV-2 detection tests, with Emergency Use Authorization from the FDA.
Fulgent Genetics (NASDAQ: FLGT) has announced that its CFO, Paul Kim, and CCO, Brandon Perthuis, will present virtually at the H.C. Wainwright BIOCONNECT 2021 Conference from January 11-14, 2021. A webcast of the presentation will be available at 6:00 a.m. ET on January 11 on the company’s Investor Relations page and accessible for 90 days. Fulgent Genetics specializes in comprehensive testing solutions and has launched various tests for SARS-CoV-2, receiving Emergency Use Authorization from the FDA for its RT-PCR tests.
FAQ
What is the current stock price of Fulgent Genetics (FLGT)?
What is the market cap of Fulgent Genetics (FLGT)?
